...
首页> 外文期刊>International Journal of Research in Medical Sciences >Comparative study of oral methotrexate and acitretin in the treatment of palmoplantar psoriasis
【24h】

Comparative study of oral methotrexate and acitretin in the treatment of palmoplantar psoriasis

机译:口服甲氨蝶呤和阿维A酸治疗掌plant型牛皮癣的比较研究

获取原文

摘要

Background: Psoriasis is chronic inflammatory skin condition. Palmoplantar psoriasis is a type where lesions are present on the palms and soles. This type affects patient's quality of life and is difficult to treat. Topical modes of treatment are not so effective and produce inadequate response. Systemic drugs are necessary in the treatment of moderate to severe disease. The objective was to compare the efficacy of oral methotrexate and acitretin in treatment of moderate to severe palmoplantar psoriasis and there side effects. Methods: 50 patients with palmoplantar psoriasis were randomized into 2 groups. Patients in group I received oral methotrexate and patients in group II received acitretin for 3 months. Baseline grading was done with Modified Psoriasis Area Severity Index (MPASI) score. MPASI score was assessed monthly. Scores at the beginning and at the end of 3 months of treatment were compared. Quality of life was assessed using a questionnaire. Results: MPASI score in group I was 57.15 ± 17.17 at baseline and 14.50 ± 13.55 at the end of 3rd month. The difference in scores before and after treatment was statistically significant. MPASI score in group II was 57.76 ± 18.60 at baseline and 21.30 ± 8.168 at the end of 3rd month. Intragroup analysis showed statistically significant difference before and after treatment. There was significant improvement in the quality of life after treatment. Conclusion: Oral methotrexate reduces the lesions faster than acitretin. Both oral methotrexate and acitretin are highly effective in treating palmoplantar psoriasis and in improving patient's quality of life.
机译:背景:牛皮癣是慢性炎症性皮肤病。掌plant牛皮癣是一种在手掌和脚底存在病变的类型。这种类型影响患者的生活质量,难以治疗。局部治疗方式不是很有效,并且反应不充分。全身性药物对于中重度疾病的治疗是必要的。目的是比较口服甲氨蝶呤和阿维A酸治疗中度至重度掌足型牛皮癣的疗效及其副作用。方法:将50例掌plant牛皮癣患者随机分为两组。第一组患者口服甲氨蝶呤,第二组患者接受阿维A 3个月。用改良的牛皮癣区域严重程度指数(MPASI)评分进行基线分级。每月评估MPASI得分。比较了3个月治疗开始和结束时的得分。使用问卷调查评估生活质量。结果:第一组的MPASI评分在基线时为57.15±17.17,在第3个月末时为14.50±13.55。治疗前后得分的差异具有统计学意义。第二组的MPASI评分在基线时为57.76±18.60,在第3个月末时为21.30±8.168。组内分析显示治疗前后有统计学差异。治疗后生活质量显着改善。结论:口服甲氨蝶呤比阿维Aretin更快地减少了病变。口服甲氨蝶呤和阿维A都可以有效治疗掌足型牛皮癣和改善患者的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号